SavedAdd your journal

Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2008 / Cilt: 42 - Sayı: 1

Immunomodulators in dermatology

Dermatolojide immünmodülatörler

Adem KÖŞLÜ
Gonca GÖKDEMİR
Eda KUMBASAR
Pages
3–8
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The purpose of this review is to introduce to our collagues potentially useful immunomodulators in clinical dermatology.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Immunomodulators include both immunostimulatory and immunosuppressive agents.
📊
Key Findings & Data:The introduction of this new class of drugs marked the beginning of the post-cortisone era in clinical dermatology.
💡
Conclusion & Impact:The purpose of this review is to introduce to our collagues potentially useful immunomodulators in clinical dermatology.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Immunomodulators include both immunostimulatory and immunosuppressive agents. The introduction of this new class of drugs marked the beginning of the post-cortisone era in clinical dermatology. Topical immunotherapy with both immunostimulatory and immunosuppressive agents show potential for effective treatment of inflammatory, infectious and neoplastic skin diseases. These agents have few side effects and have clinical effects similar to corticosteroids. The purpose of this review is to introduce to our collagues potentially useful immunomodulators in clinical dermatology.

Özet

İmmünmodülatörler, immünsuprasif ve immünstimülan özelliklere sahip olan ajanlardır. Bu yeni sınıf ilaçların klinik dermatolojide kullanıma girmesi “post-kortizon” çağın başlamış olduğunu düşündürebilir. İlerleyen teknoloji ile birlikte hergün yeni bir immünmodulatör ajan geliştirilmiştir. Bu ajanlar kortikosteroidlerle benzer klinik etkilere sahip olup, yan etkileri oldukça azdır. Topikal ve sistemik immünoterapi ajanları enflamatuar, enfeksiyöz ve neoplastik deri hastalıklarında giderek artan oranda kullanılmaya başlanmıştır. Bu derlemede dermatolojide kullanılabilecek immünmodülatörler literatür bilgileri ışığında sunulmaktadır.

🔖

Cite This Article

KÖŞLÜ, A., GÖKDEMİR, G., KUMBASAR, E. (2022). Immunomodulators in dermatology. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 42 - Sayı: 1, 3–8. https://ajindex.com/articles/622093

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Maddin M: A review of effective drugs to treat skin disease and some warnings. 5th Dermatology and Dermatopathology in Anatholia Congress. ‹stanbul, 2003
  2. Berman B, Araujo T, Lebwohl M: Immunomodulators. Dermatology. Ed. Bolognia JL, Jorizzo JL, Rapini RP: Edinburg, Mosby, 2003;2033-53
  3. Edwards L: The interferons. Dermatol Clin 2001;19:139-46
  4. Zoqua C, Nashan D, Metze D, Beiteke U, Ruping KW, Luger TA, Grabbe S: Imiquimod, pegylated interferon-alpha-2b and interleukin- 2 in the treatment of cutaneous melanoma metastases. Hautarzt. 2004;55:176-81
  5. Zioga A, Hantschke M, Klouvas G, Hatzis J, Zioga A: Hemorrhagic Kaposi sarcoma. Successful treatment with IFN-alpha. Eur J Dermatol 2004;14:37-40
  6. Asadullah K, Sterry W, Trefzer U. Cytokines: interleukin and interferon therapy in dermatology. Clin Exp Dermatol 2002;27:578-84
  7. Stevens SR, Hanifin JM, Hamilton T, Tofte SJ et al: Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998; 134: 799-804
  8. Georgiou S, Monastrli A, Pasmatzi E, Gartaganis S et al: Efficacy and safety of systemic recombinant interferon-alpha in Behcet’s disease. J Intern Med 1998;243:367-72
  9. Jumbou O, N’Guyen JM, Tessier MH, Legoux B et al: Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa. Br J Dermatol 1999;140: 427-31
  10. Lozada-Nur F, Glick M, Schubert M, Silverberg I: Use of intralesional interferon-alpha for the treatment of recurrent oral warts in patients with AIDS: a report of 4 cases. Oral Surg Oral Med Pathol Oral Rad Endod 2001;92:617-22
  11. Dinsmore W, Jordan J, O’Mahony C, McMillan A et al: Recombinant human interferon-beta in the treatment of condylomata accuminata. Int J AIDS 1997;8:622-8
  12. Gross G, Rogozinski T, Schofer H, Jablonska S et al: Recombinant interferon beta gel as an adjuvant in the treatment of recurrent genital warts: results of a placebo- controlled double blind study in 120 patients. Dermatology 1998;196:330-4. 13. http:// bmj.bmjjournals.com 14. Hengge UR, Cusini M: Topical immunomodulators for the treatment of external genital warts and molluscum contagiosum. Br J Dermatol 2003;149:15-9
  13. Sparling JD, Checketts SR, Chapman MS: Imiquimod for plantar and periungual warts. Cutis 2001;68:397-9
  14. Liota E, Smith KJ, Buckley R, Menon P,et al: Imiquimod therapy for molluscum contagiosum. J Cutan Med Surg 2000;4:76-82